RU2014146778A - Производные 7-оксо-4,7-дигидропиразоло[1,5-а]пиримидина, которые пригодны для лечения, уменьшения интенсивности или предупреждения вирусного заболевания - Google Patents
Производные 7-оксо-4,7-дигидропиразоло[1,5-а]пиримидина, которые пригодны для лечения, уменьшения интенсивности или предупреждения вирусного заболевания Download PDFInfo
- Publication number
- RU2014146778A RU2014146778A RU2014146778A RU2014146778A RU2014146778A RU 2014146778 A RU2014146778 A RU 2014146778A RU 2014146778 A RU2014146778 A RU 2014146778A RU 2014146778 A RU2014146778 A RU 2014146778A RU 2014146778 A RU2014146778 A RU 2014146778A
- Authority
- RU
- Russia
- Prior art keywords
- optionally substituted
- alkyl
- optionally
- compound
- cycloalkyl
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title claims 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims 9
- 230000003612 virological effect Effects 0.000 title claims 9
- 230000002265 prevention Effects 0.000 title claims 2
- NOSYRIKBTPXMRH-UHFFFAOYSA-N O=C1C=CNC2=CC=NN12 Chemical class O=C1C=CNC2=CC=NN12 NOSYRIKBTPXMRH-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 25
- 125000003107 substituted aryl group Chemical group 0.000 claims abstract 22
- 229910052760 oxygen Inorganic materials 0.000 claims abstract 20
- 229910052717 sulfur Inorganic materials 0.000 claims abstract 16
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract 12
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract 10
- 125000005842 heteroatom Chemical group 0.000 claims abstract 9
- 125000002950 monocyclic group Chemical group 0.000 claims abstract 9
- 125000003367 polycyclic group Chemical group 0.000 claims abstract 9
- 229910052736 halogen Inorganic materials 0.000 claims abstract 8
- 150000002367 halogens Chemical class 0.000 claims abstract 8
- 229940000425 combination drug Drugs 0.000 claims abstract 4
- 239000000203 mixture Substances 0.000 claims abstract 4
- 229940002612 prodrug Drugs 0.000 claims abstract 4
- 239000000651 prodrug Substances 0.000 claims abstract 4
- 150000003839 salts Chemical class 0.000 claims abstract 4
- 239000012453 solvate Substances 0.000 claims abstract 4
- 229910052799 carbon Inorganic materials 0.000 claims abstract 3
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 16
- 241000709664 Picornaviridae Species 0.000 claims 16
- 125000000217 alkyl group Chemical group 0.000 claims 16
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- 238000000034 method Methods 0.000 claims 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims 7
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 5
- 239000003446 ligand Substances 0.000 claims 4
- 125000001424 substituent group Chemical group 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 3
- 206010022000 influenza Diseases 0.000 claims 3
- 241000712892 Arenaviridae Species 0.000 claims 2
- 241000711573 Coronaviridae Species 0.000 claims 2
- 241000711950 Filoviridae Species 0.000 claims 2
- 241000700586 Herpesviridae Species 0.000 claims 2
- 241000712464 Orthomyxoviridae Species 0.000 claims 2
- 241000711504 Paramyxoviridae Species 0.000 claims 2
- 241000150350 Peribunyaviridae Species 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 claims 1
- 101800004538 Bradykinin Proteins 0.000 claims 1
- 102100031780 Endonuclease Human genes 0.000 claims 1
- 108010042407 Endonucleases Proteins 0.000 claims 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 claims 1
- 102100035792 Kininogen-1 Human genes 0.000 claims 1
- 239000000867 Lipoxygenase Inhibitor Substances 0.000 claims 1
- 229940123424 Neuraminidase inhibitor Drugs 0.000 claims 1
- 229940123066 Polymerase inhibitor Drugs 0.000 claims 1
- 241000712907 Retroviridae Species 0.000 claims 1
- OFHCOWSQAMBJIW-AVJTYSNKSA-N alfacalcidol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C OFHCOWSQAMBJIW-AVJTYSNKSA-N 0.000 claims 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 claims 1
- 238000004458 analytical method Methods 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 claims 1
- 229930003827 cannabinoid Natural products 0.000 claims 1
- 239000003557 cannabinoid Substances 0.000 claims 1
- 229940125400 channel inhibitor Drugs 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 238000002866 fluorescence resonance energy transfer Methods 0.000 claims 1
- 239000002911 sialidase inhibitor Substances 0.000 claims 1
- -1 substituted Chemical class 0.000 claims 1
- 0 CCC(CC)(CC(CC)(CC)C1=C(*)N(*)C2=CCC(*)=NN2C1=O)C(**)=O Chemical compound CCC(CC)(CC(CC)(CC)C1=C(*)N(*)C2=CCC(*)=NN2C1=O)C(**)=O 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261650725P | 2012-05-23 | 2012-05-23 | |
| US61/650,725 | 2012-05-23 | ||
| PCT/EP2013/060634 WO2013174931A1 (en) | 2012-05-23 | 2013-05-23 | 7-oxo-4,7 -dihydro- pyrazolo [1, 5 -a] pyrimidine derivatives which are useful in the treatment, amelioration or prevention of a viral disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2014146778A true RU2014146778A (ru) | 2016-07-10 |
Family
ID=48669866
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014146778A RU2014146778A (ru) | 2012-05-23 | 2013-05-23 | Производные 7-оксо-4,7-дигидропиразоло[1,5-а]пиримидина, которые пригодны для лечения, уменьшения интенсивности или предупреждения вирусного заболевания |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20130317021A1 (OSRAM) |
| EP (1) | EP2861232A1 (OSRAM) |
| JP (1) | JP2015521189A (OSRAM) |
| KR (1) | KR20150014506A (OSRAM) |
| CN (1) | CN104507481B (OSRAM) |
| BR (1) | BR112014029006A2 (OSRAM) |
| CA (1) | CA2874253A1 (OSRAM) |
| HK (1) | HK1204987A1 (OSRAM) |
| MX (1) | MX2014014109A (OSRAM) |
| RU (1) | RU2014146778A (OSRAM) |
| WO (1) | WO2013174931A1 (OSRAM) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014517079A (ja) | 2011-06-22 | 2014-07-17 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ａｔｒキナーゼ阻害剤として有用な化合物 |
| JP2015517555A (ja) * | 2012-05-23 | 2015-06-22 | ザヴィラ ファーマシューティカルズ ゲーエムベーハー | ７−オキソ−チアゾロピリジン炭酸誘導体及びウイルス性疾患の治療、改善又は予防におけるその使用 |
| TR201807740T4 (tr) | 2012-12-07 | 2018-06-21 | Vertex Pharma | ATR kinaz inhibitörü olarak 2-amino-6-fluoro-n-(5-fluoro-4-(4-(4-(oksetan-3-il)piperazin-1-karbonil)piperidin-1-il)piridin-3-il)pirazolo[1,5alfa]pirimidin-3-karboksamid. |
| US10035801B2 (en) | 2013-03-13 | 2018-07-31 | Genentech, Inc. | Pyrazolo compounds and uses thereof |
| EP2970288A1 (en) | 2013-03-15 | 2016-01-20 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| EP2970286A1 (en) | 2013-03-15 | 2016-01-20 | Vertex Pharmaceuticals Inc. | Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase |
| WO2014143241A1 (en) | 2013-03-15 | 2014-09-18 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| WO2015085132A1 (en) | 2013-12-06 | 2015-06-11 | Vertex Pharmaceuticals Incorporated | 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, its preparation, different solid forms and radiolabelled derivatives thereof |
| SI3152212T1 (sl) | 2014-06-05 | 2020-06-30 | Vertex Pharmaceuticals Inc. | Radioaktivno označeni derivati 2-amino-6-fluoro-N-(5-fluoro-piridin-3-IL)-pirazolo (1,5-A)pirimidin-3- karboksamidne spojine, koristni kot inhibitor kinaze ATR, priprava navedene spojine in njene različne trdne oblike |
| LT3157566T (lt) | 2014-06-17 | 2019-08-12 | Vertex Pharmaceuticals Incorporated | Vėžio gydymo būdas, panaudojant chk1 ir atr inhibitorių derinį |
| KR20170024087A (ko) | 2014-07-01 | 2017-03-06 | 렘펙스 파머수티클스 인코퍼레이티드 | 보론산 유도체 및 그의 치료적 용도 |
| CN107074880A (zh) | 2014-07-07 | 2017-08-18 | 萨维拉制药有限公司 | 二氢吡啶并吡嗪‑1,8‑二酮和它们在治疗、改善或预防病毒疾病中的用途 |
| WO2016175224A1 (ja) | 2015-04-28 | 2016-11-03 | 塩野義製薬株式会社 | 置換された多環性ピリドン誘導体およびそのプロドラッグ |
| US20170081331A1 (en) * | 2015-09-18 | 2017-03-23 | F. Hoffmann-La Roche Ag | Pyrazolopyrazines and their use in the treatment, amelioration or prevention of a viral disease |
| AU2016331955B2 (en) | 2015-09-30 | 2022-07-21 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors |
| EP3391888B1 (en) | 2015-12-15 | 2023-09-27 | Shionogi & Co., Ltd. | Medicine for treating influenza characterized by comprising combination of cap-dependent endonuclease inhibitor with anti-influenza drug |
| JP6957535B2 (ja) | 2016-06-29 | 2021-11-02 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | ピリダジノンベースの広域スペクトル抗インフルエンザ阻害剤 |
| KR20190018469A (ko) | 2016-08-10 | 2019-02-22 | 시오노기세야쿠 가부시키가이샤 | 치환된 다환성 피리돈 유도체 및 그의 프로드러그를 함유하는 의약 조성물 |
| US20200048259A1 (en) * | 2016-10-12 | 2020-02-13 | Merck Sharp & Dohme Corp. | Kdm5 inhibitors |
| WO2018071283A1 (en) * | 2016-10-12 | 2018-04-19 | Merck Sharp & Dohme Corp. | Kdm5 inhibitors |
| MA50256A (fr) | 2017-09-15 | 2020-07-22 | Aduro Biotech Inc | Composés de pyrazolopyrimidinone et leurs utilisations |
| AU2019216260B2 (en) * | 2018-01-31 | 2023-03-02 | Janssen Sciences Ireland Unlimited Company | Cycloalkyl substituted pyrazolopyrimidines having activity against RSV |
| CN113620977B (zh) * | 2021-08-24 | 2024-02-02 | 江苏弘和药物研发有限公司 | 一种噻唑烷并嘧啶酮乙酸的合成方法 |
| CN117304133A (zh) * | 2023-09-26 | 2023-12-29 | 华南农业大学 | 一种具有噻唑侧链的截短侧耳素衍生物及其制备方法和应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5475109A (en) | 1994-10-17 | 1995-12-12 | Merck & Co., Inc. | Dioxobutanoic acid derivatives as inhibitors of influenza endonuclease |
| US6559145B2 (en) * | 2000-07-12 | 2003-05-06 | Pharmacia & Upjohn Company | Heterocycle carboxamides as antiviral agents |
| CA2487211C (en) * | 2002-06-04 | 2010-09-14 | Neogenesis Pharmaceuticals, Inc. | Pyrazolo(1,5a) pyrimidine compounds as antiviral agents |
| US7550463B2 (en) | 2004-09-15 | 2009-06-23 | Shionogi & Co., Ltd. | Carbamoylpyridone derivatives having inhibitory activity against HIV integrase |
| WO2006125048A2 (en) | 2005-05-16 | 2006-11-23 | Gilead Sciences, Inc. | Hiv-integrase inhibitor compounds |
| WO2007146813A2 (en) * | 2006-06-08 | 2007-12-21 | Cylene Pharmaceuticals, Inc. | Pyridinone analogs as cell proliferation inhibitors |
| TWI518084B (zh) | 2009-03-26 | 2016-01-21 | 鹽野義製藥股份有限公司 | 哌喃酮與吡啶酮衍生物之製造方法 |
| US8835461B2 (en) | 2009-03-26 | 2014-09-16 | Shionogi & Co., Ltd. | Substituted 3-hydroxy-4-pyridone derivative |
| WO2011000566A2 (en) | 2009-06-30 | 2011-01-06 | Savira Pharmaceuticals Gmbh | Compounds and pharmaceutical compositions for the treatment of negative-sense ssrna virus infections |
| CN101671336B (zh) * | 2009-09-23 | 2013-11-13 | 辽宁利锋科技开发有限公司 | 芳杂环并嘧啶衍生物和类似物及其制备方法和用途 |
| JP2015517555A (ja) * | 2012-05-23 | 2015-06-22 | ザヴィラ ファーマシューティカルズ ゲーエムベーハー | ７−オキソ−チアゾロピリジン炭酸誘導体及びウイルス性疾患の治療、改善又は予防におけるその使用 |
-
2013
- 2013-05-23 US US13/900,940 patent/US20130317021A1/en not_active Abandoned
- 2013-05-23 CA CA2874253A patent/CA2874253A1/en not_active Abandoned
- 2013-05-23 JP JP2015513183A patent/JP2015521189A/ja active Pending
- 2013-05-23 CN CN201380025121.5A patent/CN104507481B/zh not_active Expired - Fee Related
- 2013-05-23 RU RU2014146778A patent/RU2014146778A/ru not_active Application Discontinuation
- 2013-05-23 KR KR1020147035547A patent/KR20150014506A/ko not_active Withdrawn
- 2013-05-23 WO PCT/EP2013/060634 patent/WO2013174931A1/en not_active Ceased
- 2013-05-23 MX MX2014014109A patent/MX2014014109A/es unknown
- 2013-05-23 EP EP13730131.3A patent/EP2861232A1/en not_active Withdrawn
- 2013-05-23 HK HK15105893.0A patent/HK1204987A1/xx unknown
- 2013-05-23 BR BR112014029006A patent/BR112014029006A2/pt not_active IP Right Cessation
-
2016
- 2016-06-24 US US15/191,865 patent/US20160367557A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2874253A1 (en) | 2013-11-28 |
| US20160367557A1 (en) | 2016-12-22 |
| MX2014014109A (es) | 2016-03-31 |
| EP2861232A1 (en) | 2015-04-22 |
| KR20150014506A (ko) | 2015-02-06 |
| JP2015521189A (ja) | 2015-07-27 |
| US20130317021A1 (en) | 2013-11-28 |
| CN104507481B (zh) | 2017-08-04 |
| BR112014029006A2 (pt) | 2017-06-27 |
| CN104507481A (zh) | 2015-04-08 |
| WO2013174931A1 (en) | 2013-11-28 |
| HK1204987A1 (en) | 2015-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2014146778A (ru) | Производные 7-оксо-4,7-дигидропиразоло[1,5-а]пиримидина, которые пригодны для лечения, уменьшения интенсивности или предупреждения вирусного заболевания | |
| RU2014143250A (ru) | Производные 7-оксо-тиазолопиридин карбоновой кислоты и их применение при лечении, облегчении или профилактике вирусного заболевания | |
| RU2015107803A (ru) | Производные дигидроксипиримидинкарбоновой кислоты и их применение в лечении, облегчении или предотвращении вирусного заболевания | |
| RU2014120421A (ru) | Производные гетероарилгидроксамовой кислоты и их применение при лечении, облегчении течения или профилактике вирусных заболеваний | |
| JP2015521189A5 (OSRAM) | ||
| JP2016518305A5 (OSRAM) | ||
| JP2014530838A5 (OSRAM) | ||
| RU2477723C2 (ru) | Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе | |
| RU2012144751A (ru) | Гетероциклические соединения, эффективные для ингибирования киназы | |
| JP2016508145A5 (OSRAM) | ||
| RU2014120477A (ru) | Производные пиримидин-4-она и их применение в лечении, облегчении или профилактике вирусного заболевания | |
| RU2015118647A (ru) | Аминопиримидиновые соединения в качестве ингибиторов содержащих т790м мутантных egfr | |
| BR112013014914A2 (pt) | composto, composição farmacêutica, método de tratar câncer em um paciente e uso | |
| RU2015125570A (ru) | Пиридоновые производные и их применение в лечении, уменьшении интенсивности симптомов или предотвращении вирусного заболевания | |
| BR112013001015A2 (pt) | método por tratar doenças oftálmicas que usam compostos de inibidor de cinase em formas de prodrug | |
| EA201071370A1 (ru) | Серосодержащее гетероциклическое производное, обладающее активностью ингибитора бета-секретазы | |
| JP2007284454A (ja) | 癌の処置 | |
| RU2015125307A (ru) | Комбинированная терапия | |
| RU2013127655A (ru) | Фармацевтическая комбинация паклитаксела и ингибитора cdk | |
| ECSP088293A (es) | Inhibidores de gamma secretasa, de sulfonamido n-cíclico puenteado | |
| AR076837A1 (es) | Agentes antiinflamatorios como compuestos virostaticos. | |
| EA201200472A1 (ru) | Сульфонамиды в качестве ингибиторов белков семейства bcl-2, предназначенные для лечения рака | |
| RU2013146659A (ru) | Способы лечения рака | |
| RU2013158914A (ru) | Синергическая фармацевтическая комбинация для лечения плоскоклеточной карциномы головы и шеи | |
| JP2016504376A5 (OSRAM) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20180608 |